Quantcast
Home > Quotes > BSTC
BSTC

BioSpecifics Technologies Corp. Common Stock (BSTC) Quote & Summary Data

$56.22
*  
2.18
3.73%
Get BSTC Alerts
*Delayed - data as of Nov. 20, 2018  -  Find a broker to begin trading BSTC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    BSTC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 58.58 / $ 55.94
Share Volume
25,609
50 Day Avg. Daily Volume
37,805
Previous Close
$ 58.40
52 Week High / Low
$ 66.2099 / $ 38.05
Market Cap
409,176,975
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
25,609
50 Day Avg. Daily Volume:
37,805

P/E Ratio

P/E Ratio:
25.79
Forward P/E (1y):
22.49
Earnings Per Share (EPS):
$ 2.18

Trading Range

The current last sale of $56.22 is 47.75% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 58.58 $ 66.2099
 Low: $ 55.94 $ 38.05

Company Description (as filed with the SEC)

We are a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. We currently have a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company ("Endo Global Ventures"), an affiliate of Endo International plc ("Endo"), for injectable collagenase for marketed indications and indications in development. Endo assumed this agreement when Endo acquired Auxilium Pharmaceuticals, Inc. ("Auxilium") on January 29, 2015 (the "Acquisition"). Injectable collagenase clostridium histolyticum is marketed as XIAFLEX┬« (or Xiapex┬« in Europe). On August 31, 2011, we entered into the Second Amended and Restated Development and License Agreement (the "License Agreement") with Auxilium for XIAFLEX. The License Agreement was filed with the Securities and Exchange Commission (the "SEC") on September 1, 2011 as Exhibit 10.1 to a Current Report on Form 8-K.  ... More ...  


Risk Grade

Where does BSTC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 57.99
Open Date:
Nov. 20, 2018
Close Price:
$ 56.22
Close Date:
Nov. 20, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x